Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BOOG Study Center B.V.
Sponsor

BOOG Study Center B.V.

The Netherlands Moreelsepark 1, 3511 EP Utrecht, The Netherlands

About the sponsor

Research activity in advanced triple-negative breast cancer centers on refining treatment choice through biomarker assessment, including the BRCA1-like test and response-linked outcomes in measurable and non-measurable disease.

  • BRCA1-like testing
  • First-line chemotherapy selection
  • Progression-free survival
  • Platinum-based therapy

The focus includes aligning alkylating agents, platinum agents, and taxane-based therapy with molecular features of the tumor.

About Specializations

BOOG Study Center B.V. runs clinical trials in conditions such as Hormone receptor positive HER2 negative breast cancer, Breast cancer metastatic, PIK3CA-activated mutation, Breast cancer stage III, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

5 clinical trials

Breast cancer metastatic

Not recruiting

Study comparing carboplatin-cyclophosphamide versus paclitaxel with atezolizumab as first treatment for advanced triple negative breast cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BOOG Study Center B.V.

Hormone receptor positive HER2 negative breast cancer+1

Not recruiting

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:BOOG Study Center B.V.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Two Treatment Sequences of CDK4/6 Inhibitors (Abemaciclib, Palbociclib, or Ribociclib) in Hormone Receptor Positive Advanced Breast Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:BOOG Study Center B.V.

Breast cancer stage III+2

Not recruiting

Study of Trastuzumab, Pertuzumab, and Chemotherapy Combination with Response-Guided Treatment for Patients with HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BOOG Study Center B.V.

Breast cancer

Not recruiting

Study of Trifluridine and Tipiracil in Patients with ER-Positive, HER2-Negative Advanced Breast Cancer After Chemotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Trifluridine
  • Sponsor:BOOG Study Center B.V.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.